Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Low-Dose Deferasirox in Lower Risk MDS
NCT03920657Phase 2Terminated
- Sponsor
- Fondazione Italiana Sindromi Mielodisplastiche
- Start
- Oct 2019
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of deferasirox in iron overload, sponsored by Fondazione Italiana Sindromi Mielodisplastiche. Started Oct 2019; status: terminated.
02
Drugs
deferasirox
03
Conditions
iron overload
Beyond the preview
Go deeper on NCT03920657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03920657.